Joseph Harrison, MD
Psychiatry · Owensboro, KYNPI 1104842624
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,590 of the $131,080 with a category attached, or 76.0%. It is spread thinly across 26 manufacturers, the largest accounting for just 20.9%. Reporting peaked in 2019 at $47,945 and has fallen 68.7% since, to $14,984 in 2025. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 470 payments — averaging $278.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$27K
- Otsuka America Pharmaceutical, Inc.$26K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$24K
- E.r. Squibb & Sons, L.L.C.$22K
- Sunovion Pharmaceuticals Inc.$19K
- AbbVie$9K
- plus $3K from 20 others
What the payments were for
- Consulting fees$15,06511%
- Speaking & faculty fees$99,59076%
- Travel & lodging$7,6586%
- Food & beverage$8,5997%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 56 | $27,374 |
| Otsuka America Pharmaceutical, Inc. | 75 | $26,365 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $24,299 |
| E.r. Squibb & Sons, L.L.C. | 55 | $22,118 |
| Sunovion Pharmaceuticals Inc. | 56 | $18,593 |
| AbbVie(2 entities) | 51 | $9,496 |
| Johnson & Johnson | 21 | $457 |
| Vanda Pharmaceuticals Inc. | 22 | $420 |
| Teva Pharmaceuticals USA, Inc. | 16 | $399 |
| Neurocrine Biosciences, Inc. | 14 | $306 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $258 |
| Corium, LLC | 18 | $244 |
| Lundbeck LLC | 11 | $179 |
| Ironshore Pharmaceuticals Inc. | 6 | $170 |
| Noven Therapeutics, LLC | 3 | $61 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $60 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Biogen | 2 | $43 |
| Neos Therapeutics, LP | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Indivior Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$131,080 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $162,281 |
| CaplytaLumateperone Tosylate | 47 | $94,082 |
| Abilify MaintenaAripiprazole | 32 | $80,331 |
| Invega SustennaPaliperidone Palmitate | 28 | $65,450 |
| VraylarCariprazine Hcl | 40 | $58,948 |
| AristadaAripiprazole Lauroxil | 13 | $28,339 |
| Aripiprazole | 131 | $20,431 |
| Lurasidone Hcl | 53 | $13,543 |
| Clozapine | 119 | $7,920 |
| Quetiapine Fumarate | 276 | $7,193 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 73 | $5,133 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,295 |
| Divalproex Sodium ErDivalproex Sodium | 42 | $4,194 |
| Oxcarbazepine | 38 | $3,462 |
| Lamotrigine | 432 | $3,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $306 | $162,28115 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $24,299 | $94,08247 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $26,365 | $80,33132 claims |
| Johnson & JohnsonInvega Sustenna | $457 | $65,45028 claims |
| AbbVieVraylar | $9,496 | $58,94840 claims |
| Alkermes, Inc.Aristada | $27,374 | $28,33913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $258 | $4,29511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Owensboro
- Carmen PintoElizabethtown$1.7M
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Mark WrightLexington$637K
- Carol MillerFrankfort$462K
- Ali FarooquiLouisville$393K
- Steven CroleyLexington$151K
- Stephanie HallLouisville$106K
- Jacob BishopLexington$56K
- Andrew CooleyLexington$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.